Variations in lipid levels according to menstrual cycle phase: Clinical implications

Clinical Lipidology

Volumn 6, Issue 2, 2011, Pages 225-234

  Mumford, Sunni L ^a   Dasharathy, Sonya ^a   Pollack, Anna Z ^a   Schisterman, Enrique F ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

cholesterol; estrogen; lipoprotein; menstrual cycle

Indexed keywords

ABC TRANSPORTER; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIETARY INTAKE; ESTROGEN BLOOD LEVEL; ETHNICITY; FOLLICULAR PHASE; HUMAN; LIPOPROTEIN METABOLISM; LIPOPROTEIN SYNTHESIS; LUTEAL PHASE; MENSTRUAL CYCLE; OVULATION; PHYSICAL ACTIVITY; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; UPREGULATION; WOMEN'S HEALTH;

EID: 79953816850     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/clp.11.9     Document Type: Review

References (51)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285(19), 2486-2497 (2001). Outlines clinical recommendations for treatment of high cholesterol for both men and women.
2. Lloyd-Jones D, Adams R, Carnethon M et al.: Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119(3), 480-486 (2009).
3. Adams MR, Kaplan JR, Manuck SB et al.: Inhibition of coronary artery atherosclerosis by 17-β estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 10(6), 1051-1057 (1990).
4. Grady D, Rubin SM, Petitti DB et al.: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann. Intern. Med. 117(12), 1016-1037 (1992).
5. Rijpkema AH, van der Sanden AA, Ruijs AH: Effects of post-menopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins: a review. Maturitas 12(3), 259-285 (1990).
6. Stampfer MJ, Colditz GA: Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev. Med. 20(1), 47-63 (1991).
7. Rossouw JE, Anderson GL, Prentice RL et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288(3), 321-333 (2002).
8. Hulley S, Grady D, Bush T et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280(7), 605-613 (1998).
9. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 273(3), 199-208 (1995).
10. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM: Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N. Engl. J. Med. 325(17), 1196-1204 (1991).
11. Hedon B: The evolution of oral contraceptives. Maximizing efficacy, minimizing risks. Acta. Obstet. Gynecol. Scand. 152(Suppl. 1), 7-12 (1990).
12. Krauss RM, Burkman RT: The metabolic impact of oral contraceptives. Am. J. Obstet. Gynecol. 167, 1177-1184 (1992).
13. Gaspard UJ: Metabolic effects of oral contraceptives. Am. J. Obstet. Gynecol. 157, 1029-1041 (1987).
14. Burkman RT: Lipid metabolism effects with desogestrel-containing oral contraceptives. Am. J. Obstet. Gynecol. 168, 1033-1040 (1993).
15. Knopp RH, Paramsothy P, Retzlaff BM et al.: Sex differences in lipoprotein metabolism and dietary response: basis in hormonal differences and implications for cardiovascular disease. Curr. Cardiol. Rep. 8(6), 452-459 (2006). Discusses the implications of differences in lipoprotein metabolism between men and women.
16. LaRosa JC: Women, lipoproteins and cardiovascular disease risk. Can. J. Cardiol. 6(Suppl. B), B23-B29 (1990).
17. Chu MC, Rath KM, Huie J, Taylor HS: Elevated basal FSH in normal cycling women is associated with unfavourable lipid levels and increased cardiovascular risk. Hum. Reprod. 18(8), 1570-1573 (2003).
18. Cullinane EM, Yurgalevitch SM, Saritelli AL, Herbert PN, Thompson PD: Variations in plasma volume affect total and low-density lipoprotein cholesterol concentrations during the menstrual cycle. Metabolism 44(8), 965-971 (1995).
19. Furberg AS, Jasienska G, Bjurstam N et al.: Metabolic and hormonal profiles: HDL cholesterol as a plausible biomarker of breast cancer risk. The Norwegian EBBA study. Cancer Epidem. Biomar. Prev. 14(1), 33-40 (2005).
20. Gorbach SL, Schaefer EJ, Woods M et al.: Plasma lipoprotein cholesterol and endogenous sex hormones in healthy young women. Metabolism 38(11), 1077-1081 (1989).
21. Karpanou EA, Vyssoulis GP, Georgoudi DG, Toutouza MG, Toutouzas PK: Disparate serum lipid changes between normotensive and hypertensive women during the menstrual cycle. Am. J. Cardiol. 70(1), 111-113 (1992).
22. Kim HJ, Kalkhoff RK: Changes in lipoprotein composition during the menstrual cycle. Metabolism 28(6), 663-668 (1979).
23. Larsen LF, Andersen HR, Hansen AB, Andersen O: Variation in risk indicators of cardiovascular disease during the menstrual cycle: an investigation of within-subject variations in glutathione peroxidase, haemostatic variables, lipids and lipoproteins in healthy young women. Scand. J. Clin. Lab. Invest. 56(3), 241-249 (1996).
24. Lyons Wall PM, Choudhury N, Gerbrandy EA, Truswell AS: Increase of high-density lipoprotein cholesterol at ovulation in healthy women. Atherosclerosis 105(2), 171-178 (1994). Observed cyclic changes over one cycle with 20 blood samples and also evaluated correlations between lipoprotein cholesterol levels and estradiol.
25. Muesing RA, Forman MR, Graubard BI et al.: Cyclic changes in lipoprotein and apolipoprotein levels during the menstrual cycle in healthy premenopausal women on a controlled diet. J. Clin. Endocrinol. Metab. 81(10), 3599-3603 (1996).
26. Nduka EU, Agbedana EO: Total cholesterol, high density lipoprotein cholesterol and steroid hormone changes in normal weight women during the menstrual cycle. Int. J. Gynaecol. Obstet. 41(3), 265-268 (1993). Shows cyclic changes in lipoprotein cholesterol levels with 20 blood samples taken over one cycle.
27. Pahwa MB, Seth S, Seth RK: Lipid profile in various phases of menstrual cycle and its relationship with percentage plasma volume changes. Clin. Chim. Acta 273(2), 201-207 (1998).
28. Reed RG, Kris-Etherton P, Stewart PW, Pearson TA: Variation of lipids and lipoproteins in premenopausal women compared with men and postmenopausal women. DELTA (Dietary Effects on Lipoproteins and Thrombogenic Activity) Investigators. Metabolism 49(9), 1101-1105 (2000). Compares cyclic changes during the menstrual cycle with variability in men and postmenopausal women, concluding that intraindividual variability is similar between premenopausal women and postmenopausal women and men.
29. Tonolo G, Ciccarese M, Brizzi P et al.: Cyclical variation of plasma lipids, apolipoproteins, and lipoprotein(a) during menstrual cycle of normal women. Am. J. Physiol. 269(6 Pt 1), E1101-E1105 (1995).
30. Barclay M, Barclay RK, Skipski VP et al.: Fluctuations in human serum lipoproteins during the normal menstrual cycle. Biochem. J. 96, 205-209 (1965).
31. Adlercreutz H, Tallqvist G: Variations in the serum total cholesterol and hematocrit values in normal women during the menstrual cycle. Scand. J. Clin. Lab. Invest. 11(1), 1-9 (1959).
32. Oliver MF, Boyd GS: Changes in the plasma lipids during the menstrual cycle. Clin. Sci. (Lond.) 12(2), 217-222 (1953).
33. Azogui G, Ben-Shlomo I, Zohar S, Kook A, Presser S, Aviram M: High density lipoprotein concentration is increased during the ovulatory phase of the menstrual cycle in healthy young women. Gynecol. Endocrinol. 6(4), 253-257 (1992).
34. Barnett JB, Woods MN, Lamon-Fava S et al.: Plasma lipid and lipoprotein levels during the follicular and luteal phases of the menstrual cycle. J. Clin. Endocrinol. Metab. 89(2), 776-782 (2004).
35. De Leon RG, Austin KL, Richards L, Guerrero F: Lipid and hormonal profile of Panamanian women during the menstrual cycle. Int. J. Gynecol. Obstet. 39(3), 219-226 (1992).
36. Elhadd TA, Neary R, Abdu TA et al.: Influence of the hormonal changes during the normal menstrual cycle in healthy young women on soluble adhesion molecules, plasma homocysteine, free radical markers and lipoprotein fractions. Int. Angiol. 22(3), 222-228 (2003).
37. Jones DY, Judd JT, Taylor PR, Campbell WS, Nair PP: Menstrual cycle effect on plasma lipids. Metabolism 37(1), 1-2 (1988).
38. Lebech AM, Kjaer A: Lipid metabolism and coagulation during the normal menstrual cycle. Horm. Metab. Res. 21(8), 445-448 (1989).
39. Lussier-Cacan S, Xhignesse M, Desmarais JL, Davignon J, Kafrissen ME, Chapdelaine A: Cyclic fluctuations in human serum lipid and apolipoprotein levels during the normal menstrual cycle: comparison with changes occurring during oral contraceptive therapy. Metabolism 40(8), 849-854 (1991).
40. Woods M, Schaefer EJ, Morrill A et al.: Effect of menstrual cycle phase on plasma lipids. J. Clin. Endocrinol. Metab. 65(2), 321-323 (1987).
41. Schijf CP, van der Mooren MJ, Doesburg WH, Thomas CM, Rolland R: Differences in serum lipids, lipoproteins, sex hormone binding globulin and testosterone between the follicular and the luteal phase of the menstrual cycle. Acta Endocrinol. (Copenhagen) 129(2), 130-133 (1993).
42. Mumford SL, Schisterman EF, Siega-Riz AM et al.: A longitudinal study of serum lipoproteins in relation to endogenous reproductive hormones during the menstrual cycle: findings from the BioCycle study. J. Clin. Endocrinol. Metab. 95(9), E80-E85 (2010). Largest study to date with multiple cholesterol and hormone measurements across two cycles.
43. Srivastava RA, Baumann D, Schonfeld G: In vivo regulation of low-density lipoprotein receptors by estrogen differs at the post-transcriptional level in rat and mouse. Eur. J. Biochem. 216(2), 527-538 (1993).
44. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M: Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271(5248), 518-520 (1996).
45. Zannis VI, Chroni A, Krieger M: Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J. Mol. Med. 84(4), 276-294 (2006).
46. Adlercreutz H, Tallqvist G: Variations in the serum total cholesterol and hematocrit values in normal women during the menstrual cycle. Scand. J. Clin. Lab. Invest. 11(1), 1-9 (1959).
47. Basdevant A, De Lignieres B, Bigorie B, Guy-Grand B: Estradiol, progesterone and plasma lipids during the menstrual cycle. Diabetes Metab. 7(1), 1-4 (1981).
48. Mattsson LA, Silfverstolpe G, Samsioe G: Lipid composition of serum lipoproteins in relation to gonadal hormones during the normal menstrual cycle. Eur. J. Obstet. Gynecol. Reprod. Biol. 17(5), 327-335 (1984).
49. Haines CJ, Cheung LP, Lam CW: Changes in atherogenic lipids and lipoproteins during natural and hyperstimulated cycles in healthy women. Fertil. Steril. 68(2), 231-235 (1997).
50. Ahumada Hemer H, Valles de Bourges V, Juarez Ayala J, Brito G, Díaz-Sánchez V, Garza-Flores J: Variations in serum lipids and lipoproteins throughout the menstrual cycle. Fertil. Steril. 44(1), 80-84 (1985).
51. Lamon-Fava S, Fisher EC, Nelson ME et al.: Effect of exercise and menstrual cycle status on plasma lipids, low density lipoprotein particle size, and apolipoproteins. J. Clin. Endocrinol. Metab. 68(1), 17-21 (1989).